SynCore: SynCore Biotechnology : Biotech to Acquire Rights to EndoTAG-1 from MediGene

(4-traders.com) Deal Type: Asset Transaction Deal Country: Zimbabwe Deal Status: Announced Deal Value: 0.0000 USD Deal in Brief SynCore Biotechnology Co., Ltd., a subsidiary of Sinphar Pharmaceutical Co., Ltd., has acquired all assets and takes over development activities for EndoTAG, from MediGene AG, a biotechnology company. EndoTAG-1, a novel composition of...http://www.4-traders.com/SYNCORE-BIOTECHNOLOGY-CO-20708026/news/SynCore-Biotechnology--Biotech-to-Acquire-Rights-to-EndoTAG-1-from-MediGene-21580244/